FDA Clears GE HealthCare's MIM Contour ProtégéAI+ 2.0 for Advanced Cancer Treatment Planning

GE HealthCare has announced that its MIM Contour ProtégéAI+ 2.0 software has received FDA 510(k) clearance, marking a significant advancement in AI-assisted radiation therapy planning. This update introduces new capabilities, including a Magnetic Resonance (MR) Brain model and a refined Computed Tomography (CT) Male Pelvis model, thereby enhancing the clinical applications of the software.

The FDA clearance arrives alongside a Predetermined Change Control Plan (PCCP), allowing future updates and model enhancements that can further expand the software's applications across various anatomical areas and imaging modalities. This flexibility is vital as radiation therapy continues to evolve and address increasingly complex patient needs.

Statistics from the World Health Organization highlight cancer as a leading global health challenge, responsible for nearly ten million deaths annually. Radiation therapy remains a cornerstone in treating cancer and is utilized in approximately 60% of cases, impacting over two million patients each year in the United States alone.

Dr. Ben Newton, Global Head of Oncology at GE HealthCare, emphasized the importance of accelerating innovation to support radiation therapy practices. "The introduction of MIM Contour ProtégéAI+ 2.0 represents an important step forward in advancing AI-enabled radiation therapy planning," he stated. He noted that the FDA's approval of the Predetermined Change Control Plan helps GE HealthCare to bring timely updates and improvements to market, thus enhancing the treatment planning experience.

Manual contouring is notably resource-intensive, constituting one of the most time-consuming aspects of radiation therapy planning. By leveraging AI, MIM Contour ProtégéAI+ facilitates more efficient contouring processes while ensuring accuracy. Developed using multi-institutional datasets, the software's AI models deliver contouring capabilities that match or exceed traditional methods.

The software operates with minimal user intervention, automatically processing CT and MR images and exporting results directly into treatment planning systems or MIM Workflows. This automation significantly reduces manual effort, allowing care teams to focus on developing more personalized treatment plans for patients.

J. Anders, General Manager of MIM at GE HealthCare, highlighted the user-centric design of the technology. "By automating one of the most time-intensive steps in radiation therapy planning, MIM Contour ProtégéAI+ 2.0 can help reduce treatment planning time," Anders said, "enabling care teams to focus on refining treatment plans tailored to each patient’s needs."

The updated MIM Contour ProtégéAI+ 2.0 is showcased at the American Association of Medical Dosimetrists' 51st Annual Meeting and is part of GE HealthCare's broader initiative to integrate advanced technology within their radiation oncology ecosystem.